M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 54.32 USD 4.74% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
MoonLake Immunotherapeutics?
Write Note

Operating Margin
MoonLake Immunotherapeutics

0%
Current
0%
Average
7.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-108.5m
/
Revenue
0

Operating Margin Across Competitors

Country CH
Market Cap 3.4B USD
Operating Margin N/A
Country CA
Market Cap 559.6B CAD
Operating Margin N/A
Country IN
Market Cap 9.5T INR
Operating Margin
8%
Country US
Market Cap 96.1B USD
Operating Margin
1%
Country NL
Market Cap 84.9B Zac
Operating Margin
61%
Country IL
Market Cap 435.8m ILA
Operating Margin N/A
Country ID
Market Cap 690.7T IDR
Operating Margin
38%
Country US
Market Cap 41.1B EUR
Operating Margin
1%
Country US
Market Cap 25.5B USD
Operating Margin
-54%
Country IN
Market Cap 2T INR
Operating Margin
68%
Country CH
Market Cap 20.6B CHF
Operating Margin
15%
No Stocks Found

MoonLake Immunotherapeutics
Glance View

Market Cap
3.4B USD
Industry
N/A

MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

MLTX Intrinsic Value
7.72 USD
Overvaluation 86%
Intrinsic Value
Price
M

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-108.5m
/
Revenue
0
What is the Operating Margin of MoonLake Immunotherapeutics?

Based on MoonLake Immunotherapeutics's most recent financial statements, the company has Operating Margin of 0%.